Advertisement
Advertisement

MDXG

MDXG logo

MiMedx Group, Inc

3.94
USD
Sponsored
-0.16
-4.02%
Mar 26, 15:59 UTC -4
Closed
exchange

Pre-Market

3.88

-0.06
-1.40%

MDXG Earnings Reports

Positive Surprise Ratio

MDXG beat 21 of 30 last estimates.

70%

Next Report

Date of Next Report
Apr 28, 2026
Estimate for Q1 26 (Revenue/ EPS)
$70.46M
/
-$0.01
Implied change from Q4 25 (Revenue/ EPS)
-40.33%
/
-110.00%
Implied change from Q1 25 (Revenue/ EPS)
-20.12%
/
-116.67%

MiMedx Group, Inc earnings per share and revenue

On Feb 25, 2026, MDXG reported earnings of 0.10 USD per share (EPS) for Q4 25, beating the estimate of 0.08 USD, resulting in a 16.69% surprise. Revenue reached 118.09 million, compared to an expected 108.91 million, with a 8.43% difference. The market reacted with a -6.44% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 70.46 million USD, implying an decrease of -110.00% EPS, and decrease of -40.33% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
logo
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
logo
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
logo
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
For Q4 2025, MiMedx Group, Inc reported EPS of $0.10, beating estimates by 16.69%, and revenue of $118.09M, 8.43% above expectations.
The stock price moved down -6.44%, changed from $5.28 before the earnings release to $4.94 the day after.
The next earning report is scheduled for Apr 28, 2026.
Based on 5 analysts, MiMedx Group, Inc is expected to report EPS of -$0.01 and revenue of $70.46M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement